No Data
Minsheng Securities: The results of medical insurance negotiations are now available, key products successfully included in the medical insurance catalog.
With the support of policies such as health insurance, the level of new drug research and development in China is continuously improving, the industrial scale is constantly expanding, and the number of new drugs under development in the country has jumped to the second place globally, accelerating the transition to high-quality innovation.
Akeso to Present at Citi 2024 Global Healthcare Conference and the 7th Annual Evercore HealthCONx Conference
Hong Kong Stock Announcement Gold Mining | Bosideng (03998) announces mid-term performance, the profit attributable to equity shareholders rose by 23% year-on-year to approximately 1.13 billion yuan.
Dianzhi (02586) will conduct IPO from November 28th to December 3rd, planning to globally issue 25.774 million shares; Reshaping Energy (02570) will conduct IPO from November 28th to December 3rd, planning to globally issue approximately 4.8279 million shares.
Akeso's Cervical Cancer Drug Included in China's National Reimbursement Drug List
Akeso's Carfilzomib and Ivoysna are included in the national medical insurance catalogue for 2024.
Hong Kong, November 28, 2024 /PR Newswire/ -- On November 28, Akeso (9926.HK) announced that two independently developed globally innovative bispecific antibody drugs -- Kantanz (Cadonilimab injection, PD-1/CTLA-4 bispecific) and Yidafang (Ivosidenib injection, PD-1/VEGF bispecific) have been included in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2024)" ("National Medical Insurance Catalog", which will be officially implemented from January 1, 2025). Akeso's founder, director, chairman, and president.
Express News | Akeso - Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab
No Data
No Data
MayFlower : It was predictable..
Midnite52 : yep